OPT for OPSYNVI^®

One Pill, One Fill¹

As a single-tablet combination of an ERA and a PDE5 inhibitor, OPSYNVI^® can help you to avoid the added time and complexity of 2 separate prescriptions, so that you can focus on patients, not paperwork¹

No Added Cost

Patients will pay no more for OPSYNVI^® than they would for OPSUMIT^® (macitentan) when both drugs are covered on the same formulary tier, allowing them to forgo any out-of-pocket cost of a separate PDE5 inhibitor prescription

Trial OPSYNVI^®

VOUCHER: A free trial offer is available for eligible patients to help them become familiar with OPSYNVI^®. At the conclusion of the program, you and your patient decide whether to continue treatment. Subject to one (1) use per lifetime for the patient’s first trial of OPSYNVI^®. Terms expire at the end of each calendar year and may change.

• The program is open to patients who have commercial insurance, government coverage, or no insurance coverage; however, there is no guarantee of continuous accessibility after the program ends. See full program requirements at JanssenCarePath.com